Equities

Prescient Therapeutics Ltd

PTX:ASX

Prescient Therapeutics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.043
  • Today's Change0.001 / 2.38%
  • Shares traded2.05m
  • 1 Year change-49.41%
  • Beta1.6753
Data delayed at least 20 minutes, as of Jun 14 2024 06:59 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 has completed Phase Ib expansion cohort study in relapsed and refractory T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. OmniCAR is a universal immune receptor platform being developed to enable controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumors. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumor microenvironment.

  • Revenue in AUD (TTM)697.94k
  • Net income in AUD-7.74m
  • Incorporated1986
  • Employees3.00
  • Location
    Prescient Therapeutics LtdL 4 100 Albert RdSOUTH MELBOURNE 3205AustraliaAUS
  • Phone+61 39692-7222
  • Fax+61 39077-9233
  • Websitehttps://ptxtherapeutics.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cann Group Ltd16.45m-29.28m18.71m40.00--0.3617--1.14-0.0724-0.07240.04060.11610.12370.39527.37---22.03-22.28-34.23-24.4321.11---178.07-407.570.0861-5.880.5646--114.9089.76-27.66---11.16--
Noxopharm Ltd3.90m-12.13m19.58m1.00k--2.98--5.02-0.0415-0.04150.01340.02250.2684--1.643,901.84-83.43-50.96-94.78-62.98-----310.82-191.70---1.470.00--11.3244.0219.34------
Immuron Ltd3.58m-3.88m20.29m6.00--1.16--5.67-0.017-0.0170.01570.07690.16640.64687.92596,106.70-18.06-27.48-19.86-29.5880.8777.52-108.52-296.647.79-2.850.0023--135.85-13.34-32.66--3.27--
Tryptamine Therapeutics Ltd1.21m-4.32m21.78m----3.24--18.04-0.0162-0.01620.00390.00620.2368-------84.69---120.26-------357.70-----21.620.00--------------
Acrux Ltd14.46m-709.00k22.39m43.00--3.96--1.55-0.0024-0.00240.05020.01951.29--4.86---6.34-39.91-9.21-46.0072.38---4.90-132.53----0.2861--133.7428.2992.23---16.66--
BPH Energy Ltd345.67k894.65k22.95m2.00k20.410.9868--66.400.0010.0010.00040.02030.0177--5.97--4.58-6.894.78-7.7256.39--258.50-357.76----0.0043--96.545.21179.13------
LBT Innovations Limited2.00m-21.38m24.14m17.00--8.88--12.04-0.0428-0.04280.00380.0020.10870.08192.25117,882.40-115.89-28.85-131.86-30.9994.76---1,066.62-441.763.30-6.850.5633---5.29-18.45-239.17---34.63--
Alterity Therapeutics Ltd123.46k-12.28m26.23m11.00--0.7951--212.42-0.005-0.0050.000050.00630.0044--1.5211,223.64-44.20-53.02-53.57-61.96-----9,947.97-40,995.62----0.0143--557.60-39.40-7.47---34.88--
Invion Ltd4.46m-1.50m32.12m8.00--1.80--7.20-0.0002-0.00020.00070.00280.2345--3.20---7.88-16.93-8.12-18.13-----33.60-51.63----0.00--25.7241.1827.95------
BCAL Diagnostics Ltd3.67m-5.00m33.00m----4.35--8.98-0.0227-0.02270.01660.02410.4493--3.21---61.10-54.01-67.83-62.57-----136.00-248.64---131.830.1985--298.6363.18-49.51--91.62--
Syntara Ltd9.83m-14.26m34.63m107.00--3.84--3.52-0.0197-0.01720.01360.00750.4421.582.22---64.13-27.33-97.76-34.2381.6988.37-145.11-61.991.75-262.590.0674--23.60-18.30-486.78---31.06--
Prescient Therapeutics Ltd697.94k-7.74m34.63m3.00--1.53--49.62-0.0098-0.00980.00090.02810.0276--2.32---30.58-27.61-32.59-29.03-----1,109.58-3,284.78---412.910.00--939.1629.68-36.88------
Little Green Pharma Ltd25.63m-8.15m34.70m----0.4467--1.35-0.0272-0.02720.08560.25740.27721.0512.29---8.82---9.74--53.18---31.81--1.39-18.900.0624--29.07--4.72------
Starpharma Holdings Ltd10.63m-8.40m39.97m50.00--1.16--3.76-0.0205-0.02050.02590.08370.20920.2822.10---16.53-28.47-20.70-33.6692.6771.62-79.00-391.825.22--0.0833---14.10-3.223.19--11.58--
Biotron Ltd1.65m-4.02m45.11m4.00--24.13--27.42-0.0045-0.00450.00180.00210.3587-------87.73-64.30-103.46-74.43-156.30-108.03-244.54-231.62----0.0148---8.16-2.48-25.59------
Data as of Jun 14 2024. Currency figures normalised to Prescient Therapeutics Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

0.06%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 31 Jan 2024406.50k0.05%
DFA Australia Ltd.as of 31 May 202357.23k0.01%
Data from 31 Mar 2024 - 30 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.